Cellipont Clarifies Grand Opening Date

**Cellipont Bioservices Corrects Grand Opening Date for Advanced Cell and Gene Therapy Facility in The Woodlands, Set for October 2024**

**THE WOODLANDS, TX – October 25, 2023** – Cellipont Bioservices, a contract development and manufacturing organization (CDMO) dedicated to accelerating cell and gene therapies, today issued a clarification regarding the grand opening date for its new state-of-the-art manufacturing facility in The Woodlands, Texas. The company announced that its official ribbon-cutting ceremony will now take place on **Tuesday, October 29, 2024**, correcting an initial misstatement of October 29, 2025, in a press release issued yesterday.

The adjustment in the year means the highly anticipated event is set to occur a full year earlier than first reported, bringing the advanced facility online sooner for its critical mission in the burgeoning field of regenerative medicine.

Cellipont Bioservices’ new facility represents a significant investment in the future of medical treatments, designed to provide comprehensive manufacturing services for cell and gene therapies. These therapies, which hold immense promise for treating a wide range of diseases including cancer, genetic disorders, and autoimmune conditions, require highly specialized development and manufacturing processes to move from clinical trials to patient access. As a CDMO, Cellipont Bioservices plays a crucial role in enabling pharmaceutical and biotech companies to navigate these complex stages.

“We sincerely apologize for any confusion caused by the initial typo in our announcement yesterday,” said Mike Riley, CEO of Cellipont Bioservices. “We want to ensure all our partners, community members, and stakeholders have the correct information as we look forward to this momentous occasion. The correct date for our grand opening and ribbon-cutting ceremony is indeed October 29, 2024. Our entire team is excited to host this event next year and demonstrate the advanced capabilities of our facility, which is poised to make a significant impact on bringing life-changing cell and gene therapies to patients.”

The establishment of Cellipont’s facility in The Woodlands further solidifies the Houston metropolitan area’s growing reputation as a hub for life sciences and biotechnology. The cutting-edge facility is expected to bring high-skill jobs to the region and contribute substantially to the local economy, while also bolstering Texas’s position in the global race to develop and deliver breakthrough therapies.

The facility’s design and operational focus are on scalability, quality, and regulatory compliance, essential factors for therapies that are often personalized and require meticulous production. Once fully operational, it will support the manufacturing needs from early-stage clinical development through commercial supply, addressing a critical bottleneck in the cell and gene therapy ecosystem.

Further details regarding the grand opening event and invitation logistics will be shared by Cellipont Bioservices in the months leading up to October 29, 2024. For more information about Cellipont Bioservices and its mission, please visit their official website.